guest ::
TY - THES AU - Syben, Annabell TI - Nervencheck zur Frühdiagnostik einer Chemotherapie-induzierten Neuropathie (N-CHECK) PB - Rheinisch-Westfälische Technische Hochschule Aachen VL - Dissertation CY - Aachen M1 - RWTH-2025-10656 SP - 1 Online-Ressource : Illustrationen PY - 2025 N1 - Veröffentlicht auf dem Publikationsserver der RWTH Aachen University 2026 N1 - Dissertation, Rheinisch-Westfälische Technische Hochschule Aachen, 2025 AB - Chemotherapy-induced neuropathy (CIPN) is a common side effect of platinum based cytostatic therapies. It encompasses a spectrum of symptoms ranging from hypaesthesia with impaired gait, stance and fine motor skills to painful dysaesthesia and allodynia and significantly impairs the quality of life of those affected. In around a third of patients, CIPN develops into a chronic condition. To date, there are neither proven effective preventive strategies nor a standardised procedure for diagnosis and treatment. In our pilot study " Nerve check for early diagnosis of a chemotherapy-induced neuropathy (N-CHECK)”, CIPN was investigated as a common adverse effect of platinum derivatives in patients with solid tumours using quantitative sensory testing (QST) according to the standardised examination protocol of the German Research Network on Neuropathic Pain (DFNS). The QST examines thermal and mechanical perception and pain thresholds to record the subjectively experienced pain phenotype. In N-CHECK it was used before and six to ten weeks after the start of the potentially CIPN-inducing therapy and the data collected was compared in a pre-post analysis. In addition, the Eastern Cooperative Oncology Group Performance Status (ECOG PS), the German short form of the Patient Health Questionnaire (PHQ-D) for screening anxiety and depression, and the Functional Assessment for Cancer Therapy - General (FACT-G) for assessing cancer-specific health-related quality of life were used as criteria for the toxicity of the platinum derivatives. To shed light on the current state of research regarding CIPN, a systematic literature review was completed. Overall, the patients showed significant new heat hypoalgesia after the start of chemotherapy as a sign of damage to small nerve fibres. In addition, there was a reduction in physical functioning and a significantly higher level of suffering from the side effects of the therapy. There were indications of a deterioration in the quality of life and impairment of the mental health of individuals. The systematic literature review emphasised the need for further research to be able to help CIPN patients at an early stage. This pilot study provided a basis for the early diagnosis of chemotherapy-induced neuropathy. Further research is needed to validate the results so that the diagnosis of CIPN can be improved and patients can be treated earlier and in a more targeted manner. LB - PUB:(DE-HGF)11 DO - DOI:10.18154/RWTH-2025-10656 UR - https://publications.rwth-aachen.de/record/1023672 ER -